» Articles » PMID: 23557481

Structural and Functional Interactions of the Prostate Cancer Suppressor Protein NKX3.1 with Topoisomerase I

Overview
Journal Biochem J
Specialty Biochemistry
Date 2013 Apr 6
PMID 23557481
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

NKX3.1 (NK3 homeobox 1) is a prostate tumour suppressor protein with a number of activities that are critical for its role in tumour suppression. NKX3.1 mediates the cellular response to DNA damage by interacting with ATM (ataxia telangiectasia mutated) and by activation of topoisomerase I. In the present study we characterized the interaction between NKX3.1 and topoisomerase I. The NKX3.1 homeodomain binds to a region of topoisomerase I spanning the junction between the core and linker domains. Loss of the topoisomerase I N-terminal domain, a region for frequent protein interactions, did not affect binding to NKX3.1 as was shown by the activation of Topo70 (N-terminal truncated topoisomerase I) in vitro. In contrast, NKX3.1 interacts with the enzyme reconstituted from peptide fragments of the core and linker active site domains, but inhibits the DNA-resolving activity of the reconstituted enzyme in vitro. The effect of NKX3.1 on both Topo70 and the reconstituted enzyme was seen in the presence and absence of camptothecin. Neither NKX3.1 nor CPT (camptothecin) had an effect on the interaction of the other with topoisomerase I. Therefore the interactions of NKX3.1 and CPT with the linker domain of topoisomerase I are mutually exclusive. However, in cells the effect of NKX3.1 on topoisomerase binding to DNA sensitized the cells to cellular toxicity and the induction of apoptosis by low doses of CPT. Lastly, topoisomerase I is important for the effect of NKX3.1 on cell survival after DNA damage as topoisomerase knockdown blocked the effect of NKX3.1 on clonogenicity after DNA damage. Therefore NKX3.1 and topoisomerase I interact in vitro and in cells to affect the CPT sensitivity and DNA-repair functions of NKX3.1.

Citing Articles

The Homeobox Transcription Factor NKX3.1 Displays an Oncogenic Role in Castration-Resistant Prostate Cancer Cells.

Budreika A, Phoenix J, Kostlan R, Deegan C, Ferrari M, Young K Cancers (Basel). 2025; 17(2.

PMID: 39858088 PMC: 11763476. DOI: 10.3390/cancers17020306.


Differential Expression Profile of lncRNA in Glioma Cells and the Effect of lncRNA NKX3-1 on Glioma Cells Through Fem1b/SPDEF Pathway.

Cai Y, Wang M, Cui Y, Tan Z, Jiang Y Front Oncol. 2021; 11:706863.

PMID: 34350121 PMC: 8328487. DOI: 10.3389/fonc.2021.706863.


The Role of Nkx3.1 in Cancers and Stemness.

Antao A, Ramakrishna S, Kim K Int J Stem Cells. 2021; 14(2):168-179.

PMID: 33632988 PMC: 8138659. DOI: 10.15283/ijsc20121.


CRISPR/Cas9-Mediated Point Mutation in Prolongs Protein Half-Life and Reverses Effects Allelic Loss.

Bowen C, Shibata M, Zhang H, Bergren S, Shen M, Gelmann E Cancer Res. 2020; 80(21):4805-4814.

PMID: 32943441 PMC: 7642110. DOI: 10.1158/0008-5472.CAN-20-1742.


Chemotherapeutic Drugs Inhibiting Topoisomerase 1 Activity Impede Cytokine-Induced and NF-κB p65-Regulated Gene Expression.

Riedlinger T, Bartkuhn M, Zimmermann T, Hake S, Nist A, Stiewe T Cancers (Basel). 2019; 11(6).

PMID: 31242600 PMC: 6627772. DOI: 10.3390/cancers11060883.


References
1.
Simmons D, Roy R, Chen L, Gai D, Trowbridge P . The activity of topoisomerase I is modulated by large T antigen during unwinding of the SV40 origin. J Biol Chem. 1998; 273(32):20390-6. DOI: 10.1074/jbc.273.32.20390. View

2.
Stewart L, Ireton G, Champoux J . Reconstitution of human topoisomerase I by fragment complementation. J Mol Biol. 1997; 269(3):355-72. DOI: 10.1006/jmbi.1997.1056. View

3.
Kos L, Chiang C, Mahon K . Mediolateral patterning of somites: multiple axial signals, including Sonic hedgehog, regulate Nkx-3.1 expression. Mech Dev. 1998; 70(1-2):25-34. DOI: 10.1016/s0925-4773(97)00168-8. View

4.
Asatiani E, Huang W, Wang A, Rodriguez Ortner E, Cavalli L, Haddad B . Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 2005; 65(4):1164-73. DOI: 10.1158/0008-5472.CAN-04-2688. View

5.
Donjacour A, Sciavolino P, Kim M, Desai N, Young P, Norton C . Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 1999; 13(8):966-77. PMC: 316645. DOI: 10.1101/gad.13.8.966. View